FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome

Karam, Maroun; Ata, Ashar; Irish, Kevin; Feustel, Paul J.; Mottaghy, Felix M.; Stroobants, Sigrid; Verhoef, Gregor; Chundru, Surya; Douglas-Nikitin, Vonda; Wong, Ching-Yee Oliver; Brepoels, Lieselot

doi:10.1097/mnm.0b013e32832e0c13

Cited by 44 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other investigators have reported that a higher SUV max at baseline is associated with worse survival [22,23]. In these reports, the cutoff SUV max values that stratified patients into high risk versus low risk groups were 5 and 6, respectively.…”

Section: Discussionmentioning

confidence: 97%

Utility of positron emission tomography scans in mantle cell lymphoma

et al. 2011

View full text Add to dashboard Cite

Positron emission tomography (PET) scans are widely used in patients with lymphoma but little is known about their utility in mantle cell lymphoma (MCL). MCL patients were included from two prospective trials and one observational study at our institution. A total of 276 PET scans were performed among 52 patients. After a median follow-up of 37.5 months, the 3-year event-free survival (EFS) and overall survival (OS) were 73% (95% confidence interval [CI]: 61-85%) and 92% (95% CI 85-100%), respectively. There were 34 pretreatment PET scans, 26 interim, 28 end-of-treatment, 162 surveillance, and 26 scans at relapse or beyond. Pretreatment PETs were positive in 94%. A negative interim or end-of-therapy PET scan was not significantly associated with better EFS or OS, but no deaths were observed in patients who had a negative interim or end-of-therapy PET. Surveillance PET scans had a high false positive rate (35%) and low positive predictive value (8%). PET scans contributed to an earlier diagnosis of relapse in only two out of the 18 patients (11%) who relapsed. PET scans did not meaningfully contribute to staging or surveillance of MCL patients in this study. There was a trend toward improved survival in patients who had a negative end-of-therapy PET scan.

show abstract

Section: Discussionmentioning

confidence: 97%

Utility of positron emission tomography scans in mantle cell lymphoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…En LNH del manto una captación alta se asocia a presencia de blastoides y variante de células grandes, lo que se sabe determina un curso más agresivo de la enfermedad 15 . Karma y cols describen que un SUVmax > 5 se asoció a menor sobrevida en pacientes con LNH del manto (sobrevida a 5 años 34% vs 87% en pacientes con SUVmax ≤ 5) 17 . Entonces, en algunos casos la valoración pronós-tica pretratamiento dependería no sólo de la extensión de la enfermedad, sino también de la avidez de captación de F18-FDG.…”

Section: Discussionunclassified

Compromiso nodal y extranodal detectado con PET/CT en linfoma en etapificación

et al. 2017

Rev. chil. radiol.

View full text Add to dashboard Cite

IntroducciónEl término linfoma se utiliza para identificar un grupo heterogéneo de neoplasias que se originan en las células de los órganos del tejido linfoide y que tienen comportamiento biológico y clínico diferente. Históricamente divididas en 2 grandes categorías:Compromiso nodal y extranodal detectado con PET/CT en linfoma en etapificación Ladrón de Guevara D., et al. Compromiso nodal y extranodal detectado con PET/CT en linfoma en etapificación. Rev Chil Radiol 2017; 23(3) (SUVmax promedio 13,0±9,7), un 86,3% presentó compromiso nodal (51,9% a ambos lados del diafragma, 24,5% sólo sobre el diafragma) y 66,7% compromiso extranodal (42,6% médula ósea, 22,1% muscular,16,2% renal). De los 30 pacientes con LH (SUVmax promedio 14,6±6,0), el 100% tuvo compromiso nodal (63,3% sólo sobre el diafragma, 36,7% sobre y bajo el diafragma), y 30% compromiso extranodal (66,7% médula ósea, 22,2% pulmón . Aun cuando ambas neoplasias son sensibles a la quimioterapia y a la radioterapia, sus tasas de curación son diferentes. El LH puede curarse hasta en un 80% de los pacientes empleando tratamientos tradicionales y terapias de rescate, el LNH se cura en Resumen. Objetivo: Describir el compromiso nodal y extranodal visible con PET/CT en los distintos tipos y subtipos de linfoma en etapificación. Pacientes y método: Se revisaron los PET/CT con F18-FDG realizados a pacientes con linfoma en etapificación, determinando frecuencia y localización del compromiso nodal y extranodal, e intensidad de captación de F18-FDG medida mediante SUVmax. Resultados: De los 102 pacientes con LNH

show abstract

“…At present, there are very few prospective data to support the use FDG-PET CT for staging, during therapy and after therapy outside of a clinical trial [Brepoels et al 2008;Gill et al 2008aGill et al , 2008b. However, in the context of relatively intensive chemotherapy regimens, FDG-PET CT has shown to have prognostic value, with higher progression-free survival (PFS) and OS rates reported in MCL patients who are FDG-PET-negative at the completion of chemotherapy [Karam et al 2009;Schaffel et al 2009;Mato et al 2012].…”

Section: Discussionmentioning

confidence: 99%

Mantle cell lymphoma: observation to transplantation

Sweetenham

2014

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Abstract:Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.

show abstract

FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome

Abstract: Staging FDG PET/CT is superior to CT and may be used in the future for identification of a subset of MCL patients with a better outcome than otherwise expected.

Cited by 44 publications

References 12 publications

Utility of positron emission tomography scans in mantle cell lymphoma

Utility of positron emission tomography scans in mantle cell lymphoma

Compromiso nodal y extranodal detectado con PET/CT en linfoma en etapificación

Mantle cell lymphoma: observation to transplantation

Contact Info

Product

Resources

About